

Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. • Phone: 67 603 603 • Fax: 91-22-6694 3127 Email : info@jenburkt.com • www.jenburkt.com • CIN No. L24230MH1985PLCO36541

## Statement of standalone Unaudited Financial Results for the quarter & Nine months ended on 31/12/2014

Sr.	Particulars	Quarter ended			Nine Month Ended		(Rs. in Lacs ) Year ended	
No.		71 =			Time Month Black		1 car ended	
		31/12/2014	30/09/2014	31/12/2013	31/12/2014	31/12/2013	31/03/2014	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Income from Operations							
	(a) Net Sales/Income from Operations (Net of Excise Duty)	2133.92	2222.40	1948.38	6277.25	5626.80	7620.0	
	(b) Other Operating Income	4.31	1.95		7.98	2.15	2.4	
				0.00	. 7.50	2.13	217.	
	Total Income from Operations (Net)	2138.23	2224.35	1948.38	6285.23	5628.95	7622.4	
2	Expenses							
	(a) Cost of Materials Consumed	685.31	763.17	716.39	1994.04	1806.70	2473.4	
	(b) Purchases of Stock in Trade	0.00	0.47	0.00	1.15	0.00	0.6	
	© Changes in Inventories of Finished Goods, Work-in-progress and	5000 5000	200000000					
	Stock-in-Trade	-39.39	-71.80		-83.08	14.39	77.0	
	(d) Employee benefits Expense	488.61	454.13	429.71	1431.69	1273.81	1696.5	
	(e) Depriciation and amortisation Expense	68.34	62.50	37.50	188.34	112.50	155.3	
	(f) Other Expenses (Any Item exceeding 10% of the total expense relating to continuing operations to shown separately)				C			
	relating to continuing operations to snown separately)	E94 40	C2C 1F	C14 CO	1010 55	4.650.40	2000 4	
	Total Expenses	584.40 <b>1787.27</b>	626.15 <b>1834.62</b>	614.60	1818.55	1658.18	2223.13	
-	Profit / (Loss) from Operations before other income, finance cost	1/0/.2/	1034.02	1671.49	5350.69	4865.58	6626.08	
3	and exceptional items (1-2)	350.96	389.73	276.89	934.54	763.37	996.37	
4	Other Income	18.28	24.43	. 51.76	49.05	89.65	161.10	
	Profit / (Loss) from Ordinary activities before finance costs and	10.20	24.43	, 31.70	45.05	83.03	101.10	
5	exceptional items (3+4)	369.24	414.16	328.65	983.59	853.02	1157.53	
6	Finance Cost	10.22	4.66	58.24	26.41	129.27	126.50	
. 7	Profit / (Loss) from ordinary activities after finance cost but before					223/27	120,50	
,	exceptional items (5-6)	359.02	409.50	270.41	957.18	723.75	1031.03	
8	Exceptional Items	0.00	0.00	0.00	0.16	0.90	1.85	
9	Profit / (Losss) from Ordinary activities before tax (7+8)	359.02	409.50	270.41	957.34	724.65	1032.88	
10	Tax Expense							
	Current	123.00	120.00	75.00	303.00	205.00	289.93	
	Defferred	-65.52	-21.25	0.00	-86.77	0.00	-7.68	
11	Net Profit / (Loss) from Ordinary activities after tax (9-10)	301.54	310.75	195.41	741.11	519.65	750.63	
12	Extra ordinary items (Net of tax expense					·		
40	)	0.00	0.00	0.00	0.00	0.00	0.00	
13	Net Profit / (Loss) for the period (11+12)	301.54	310.75	195.41	741.11	519.65	750.63	
14	Share of Profit / (Loss of Associates) Minority Interest							
13	Net Profit / (Loss) after taxes, minority interest and share of					///		
16	profit/(loss) of Associates (13+14+15)	201 54	210.75	105 41	744 44	E40.65	750.55	
_	Paid-up equity share capital (Face Value of Rs. 10/- each)	301.54	310.75	195.41	741.11	519.65	750.63	
17	r ald-up equity share capital (race value of 10/1- each)	464.93	464.93	464.93	464.93	464.03	464.03	
	Reserve excluding Revaluation Reserves (as per balance sheet of	404.55	404,33	404.93	404.95	464.93	464.93	
18	previous accounting year)	О	0	0	О	0	2265.73	
	Earnings Per Share (EPS) (before extraordinary items) (of Face							
19 i	Value of Rs. 10/- each) (not annualised)							
-	(a) Pacie							
	(a) Basic	6.49	6.68	4.20	15.94	11.18	16.15	
	(b) Diluted Earnings Per Share (EPS) (after extraordinary items) (of Face Value	6.49	6.68	4.20	15.94	11.18	16.15	
19 ii	of Rs. 10/- each - not annuallised)	2						
	or no. 20/- cacii - not annualiseu)			I				
	(a) Basic	6.49	6.68	4.20	15.94	11.18	16.15	





Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. • Phone: 67 603 603 • Fax: 91-22-6694 3127 Email: info@jenburkt.com • www.jenburkt.com • CIN No. L24230MH1985PLCO36541

\*\*\* 2 \*\*\*

### PART-II INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2014

Sr. No.	Particulars	Q	uarter Ende	ed	9 months ended		Year Ended		
		31.12.14	30.09.14	31.12.13	31.12.14	31.12.13	31.03.14		
			Audited						
A.	Particulars of Shareholding								
1	Public shareholding								
	- Number of shares	2462736	2466223	2479955	2462736	2479955	2472690		
	- Percentage of shareholding	52.97	53.05	53.34	52.97	53.34	53.18		
2	Promoters and Promoter Group Shareholding								
	a) Pledged / Encumbered								
	- Number of shares	0	. 0	0	0	0	0		
	<ul> <li>Percentage of shares (as a % of the total shareholding of promoter and promoter group)</li> </ul>	0	0	0	0	0	0		
•	<ul> <li>Percentage of shares (as a % of the total share capital of the company)</li> </ul>			8					
	b) Non - encumbered			147-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-					
	- Number of shares	2186564	2183077	2169345	2186564	2169345	2176610		
	<ul> <li>Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)</li> </ul>	100.00	100.00	100.00	100.00	100.00	100.00		
	<ul> <li>Percentage of shares (as a % of the total share capital of the company)</li> </ul>	47.03	46.95	46.66	47.03	46.66	46.82		
	Particulars	Quarter ended on 31.12.2014							
В	INVESTOR COMPLAINTS								
	Pending at the beginning of the quarter			1	lil .				
	Received during the quarter	Nil							
7	Disposed of during the quarter	Nil							
	Remaining unresolved at the end of the quarter	Nil							

#### Notes:

- 1 The above unaudited financial results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meetings held on 27.01.2015.
- 2 The Limited Review of the above results has been carried out by the Statutory Auditors.
- 3 The Company is dealing exclusively in Pharmaceuticals Business Segment, hence segmentwise presentation of financial results is not required.
- 4 Consequent to enactment of the Companies Act, 2013 ('the Act') and its applicability for accounting periods commencing after 1st April, 2014, the company has computed depreciation with reference to the useful life of tangible assets prescribed under Schedule II to the Act. In case of any asset whose life has completed as above, the carrying value, as at 1st April 2014 has been adjusted to the Opening Profit and Loss Appropriation Account and in other cases the carrying value has been depreciated over the remaining of the revised life of the assets rounded to the year and recognized in the Statement of Profit and Loss. In accordance with this Opening Profit and Loss Appropriation Account is adjusted in current year by Rs 11.98 lacs (Rupees Eleven lacs ninety eight thousand) being WDV of assets completing its useful life and Rs 3.89 lacs (Rupees Three lacs eighty nine thousand) being deferred tax reversal thereon.
- 5 Prior period figures have been regrouped/recast wherever necessary for comparative purposes.

Place : Mumbai Date : 27/01/2015 By order of the Board, For Jenburkt Pharmaceuticals Ltd.

(Ashish U. Bhuta)

Chairman and Managing Director.

# D.L.ARORA & Co. CHARTERED ACCOUNTANTS

Place: Mumbai.

Date: 27<sup>th</sup> January, 2015.

9/425, BHAGYODAYA, KHER NAGAR, BANDRA [EAST] MUMBAI- 400 051. TEL: 32911248 26470541

FAX: 26474719

#### LIMITED REVIEW REPORT

TO THE BOARD OF DIRECTORS, JENBURKT PHARMACEUTICALS LIMITED, Nirmala Apartments, 93 J.P. Road, Andheri -West, Mumbai -400058.

We have reviewed the accompanying statement of unaudited financial results ('the statements') of JENBURKT PHARMACEUTICALS LIMITED ('the Company') for the quarter ended on December 31st 2014, except for the disclosures regarding 'Public share holding' and 'Promoter and Promoter Group Share holding', which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 27th January 2015. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurances as to whether the Financial Statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedure applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable accounting standards notified pursuant to Companies(Accounting Standards) Rules, 2006 which continue to apply under the section 133 of the Companies Act, 2013 ,read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

> For D.L.Arora & Co. Chartered Accountants Firm Regn No.: 100545W

> > RIV.

Dilip Arora Proprietor

M. No.: 036152

\\Pc-3-pc\e\My Documents - 1\Jenburkt\JPL 13-14\Limited review report.(31.12.2014)

